Autopsy report · NCT03330197

A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG

“Sponsor decision due to slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 11 months before it stopped.
• 6 participants enrolled.
• Results were posted on the registry 3 years 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Alaunos Therapeutics

Sponsor type

Industry

Conditions

Pediatric Brain Tumor; Diffuse Intrinsic Pontine Glioma

Interventions

Ad-RTS-hIL-12; Oral Veledimex - Arm 1 (Pediatric Brain Tumor); Oral Veledimex - Arm 2 (DIPG)

Participants

6

Sites

3

Countries

United States

Trials that died the same way

• Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
  “Sponsor decision due to low accrual” (85% match in meaning)
• Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
  “Decision by funding sponsor due to poor accrual” (76% match in meaning)
• The Effect of a Probiotic Strain on Aspirin-induced GI Damage
  “Decision made by Sponsor” (73% match in meaning)
• PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
  “Sponsor Decision” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.